Next-generation isotope production site aims to boost global supply and advance precision medicine
Philadelphia, Pennsylvania,24 March 2026 – TerraPower Isotopes has announced plans to build a major new manufacturing facility in Philadelphia, marking a significant step forward in the fight against cancer. The new site will focus on producing actinium-225, a rare and powerful isotope used in advanced cancer treatments.
The facility will be built in the Bellwether District and is expected to begin production in 2029. Once completed, it will operate under current Good Manufacturing Practices (cGMP), ensuring high-quality and safe production standards. Along with expanding its existing operations in Everett, Washington, the company aims to increase its production capacity by 20 times.
TerraPower Isotopes is part of TerraPower, a company known for developing innovative nuclear technologies in both energy and healthcare. Through its work, the company is helping to bring new types of cancer treatments to market, especially those based on targeted alpha therapies. These therapies use isotopes like actinium-225 to directly attack cancer cells while limiting damage to healthy tissue.
Currently, actinium-225 produced by the company is already being used in clinical trials worldwide. The new Philadelphia facility is expected to further strengthen supply, making it more accessible for researchers and pharmaceutical companies working on next-generation cancer drugs.
The company selected Philadelphia after an extensive search process that reviewed more than 350 potential sites across the United States. The Bellwether District stood out due to its strong life sciences ecosystem, access to infrastructure, and proximity to research institutions and healthcare organizations.
Industry leaders have welcomed the move, noting that the region is becoming a key hub for medical innovation. The new facility is expected to support collaboration between scientists, healthcare providers, and biotech companies, helping accelerate the development of new treatments.
TerraPower, founded by Bill Gates and a group of innovators, continues to focus on solving global challenges through nuclear science. Its work spans clean energy, environmental sustainability, and medical advancements. With this new investment, the company is reinforcing its commitment to improving healthcare outcomes and expanding access to life-saving technologies.
As demand for precision medicine and advanced cancer therapies continues to grow, TerraPower Isotopes’ expansion reflects a broader shift toward more targeted and effective treatment approaches. The new facility is expected to play a key role in supporting future breakthroughs in oncology.
